Coexpression of Smac/DIABLO and Estrogen Receptor in breast cancer
Por:
Espinosa M., Lizárraga F., Vázquez-Santillán K., Hidalgo-Miranda A., Piña-Sánchez P., Torres J., García-Ramírez R.A., Maldonado V., Melendez-Zajgla J., Ceballos-Cancino G.
Publicada:
1 ene 2021
Resumen:
BACKGROUND: Smac/DIABLO is a proapoptotic protein deregulated in breast cancer, with a controversial role as a tumor marker, possibly due to a lack of correlative mRNA and protein analyses. OBJECTIVE: To investigate the association of Smac/DIABLO gene and protein levels with clinical variables in breast cancer patients. METHODS: Smac/DIABLO mRNA expression was analyzed by qPCR in 57 frozen tissues, whereas protein levels were assessed by immunohistochemistry in 82 paraffin-embedded tissues. Survivin mRNA levels were also measured. In vitro assays were performed to investigate possible regulators of Smac/DIABLO. RESULTS: Higher levels of Smac/DIABLO mRNA and protein were found in estrogen receptor (ER)-positive samples (p= 0.0054 and p= 0.0043, respectively) in comparison to ER-negative tumors. A negligible positive association was found between Smac/DIABLO and survivin expression. In vitro assays showed that Smac/DIABLO is not regulated by ER and, conversely, it does not participate in ER expression modulation. CONCLUSIONS: mRNA and protein levels of Smac/DIABLO were increased in ER-positive breast tumors in comparison with ER-negative samples, although the mechanism of this regulation is still unknown. Public databases showed a possible clinical relevance for this association. © 2021-IOS Press. All rights reserved.
Filiaciones:
Espinosa M.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Functional Cancer Genomics Laboratory, Mexico City, Mexico
Lizárraga F.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Epigenetic Laboratory, Mexico City, Mexico
Vázquez-Santillán K.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Epigenetic Laboratory, Mexico City, Mexico
Hidalgo-Miranda A.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Cancer Genomics Laboratory, Mexico City, Mexico
Piña-Sánchez P.:
Instituto Mexicano Del Seguro Social, Cmn S Xxi, Oncology Research Unit, Molecular Oncology Laboratory, Mexico City, Mexico
Torres J.:
Instituto Mexicano Del Seguro Social, Cmn S Xxi, Unity of Research in Infectious Diseases, Mexico City, Mexico
García-Ramírez R.A.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Functional Cancer Genomics Laboratory, Mexico City, Mexico
Maldonado V.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Epigenetic Laboratory, Mexico City, Mexico
Melendez-Zajgla J.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Functional Cancer Genomics Laboratory, Mexico City, Mexico
Ceballos-Cancino G.:
Instituto Nacional de Medicina Genómica, Department of Basic Research, Functional Cancer Genomics Laboratory, Mexico City, Mexico
|